|
Guest
|
Most recent articles on colorectal cancer:
Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in
colorectal cancer: Prognostic significance and clinicopathologic
correlations.
Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z,
Papavassiliou AG, Kalofonos H.
Cell Oncol. 2009;31(3):235-47.
Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-
catenin signaling.
James RG, Biechele TL, Conrad WH, Camp ND, Fass DM, Major MB, Sommer
K, Yi X, Roberts BS, Cleary MA, Arthur WT, MacCoss M, Rawlings DJ,
Haggarty SJ, Moon RT.
Sci Signal. 2009 May 26;2(72):ra25.
C-reactive protein and colorectal adenomas: Self Defense Forces Health
Study.
Otake T, Uezono K, Takahashi R, Fukumoto J, Tabata S, Abe H, Tajima O,
Mizoue T, Ohnaka K, Kono S.
Cancer Sci. 2009 Apr;100(4):709-14.
Barriers to colorectal cancer screening: a case-control study.
Cai SR, Zhang SZ, Zhu HH, Zheng S.
World J Gastroenterol. 2009 May 28;15(20):2531-6.
Poly(ADP-ribose) polymerase inhibition down-regulates expression of
metastasis-related genes in CT26 colon carcinoma cells.
Li M, Threadgill MD, Wang Y, Cai L, Lin X.
Pathobiology. 2009 May;76(3):108-16.
FDG-PET: for early prediction of response to the first-line
chemotherapy in metastatic colorectal cancer?
Arslan C, Kilickap S.
Ann Oncol. 2009 Jun;20(6):1149-50.
Looking ahead: what will change in colorectal cancer treatment?
Saltz LB.
Gastrointest Cancer Res. 2009 Mar;3(2 Suppl):S16-8.
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scimedweb at (no spam) mail.com) |
|
|
